Bharat biotech

Bharat Biotech launches nasal vaccine iNCOVACC

iNCOVACC will be the world’s first COVID-19 booster dose. It will give India more options to choose from when it comes to third doses or precautionary doses

Pfizer CEO gets grilled at Davos; India stands vindicated for not buckling under pressure

A video of Chief Executive Officer of US-based pharma giant Pfizer Alberta Bourla dodged media’s queries on the efficacy of its Covid vaccine against transmission of the virus on the sidelines of the ongoing World Economic Forum meeting, In the viral clip from the interview, a journalist is asking Bourla some tough questions like when […]

Bharat Biotech’s Covid nasal vaccine gets CDSCO approval

Bharat Biotech’s Intranasal Vaccine receives both Primary series and Heterologous booster approval from from the Central Drugs Standard Control Organisation (CDSCO). This is first ever Intranasal Vaccine approved under restricted emergency use for 18+ for heterologous booster doses.. This vaccine was tested on 3100 candidates at 14 trial sites across India majorly for immunogenicity during […]

Bharat Biotech Completes Phase III Trial Of Intranasal Covid Vaccine

Bharat Biotech International Limited (BBIL) on Monday said that it has completed the phase III trials and booster doses for the Covaxin Intranasal Covid-19 vaccine.

Japan Approves Covaxin Booster Dose For Travellers

KOLKATA: Japan has approved the booster shot of Covaxin, the anti-Covid vaccine developed by India’s Bharat Biotech, for travellers, the drug maker announced on Friday. “We are proud to announce that Japan has approved COVAXIN booster dose for travellers. Another global recognition of the effectiveness of our universal COVID vaccine,” Bharat Biotech stated. Earlier in April, […]

Bharat Biotech Partners With 2 Others For ‘Variant-Proof’ Covid Vaccine

NEW DELHI: India’s Bharat Biotech, Switzerland’s ExcellGene SA and University of Sydney have come together to manufacture a “variant-proof” Covid-19 vaccine. The SARS-CoV-2 vaccine candidate will be developed under the recently-approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI). Under this initiative, CEPI will provide funding up to USD 19.3 million for phase […]

Covaxin Safe, Highly Immunogenic In Children, Says Study

NEW DELHI: Bharat Biotech’s Covaxin has proven to be ‘safe, well-tolerated, and highly immunogenic’ in children in Phase II/III studies, the results of which are published in the prestigious Lancet journal. The study said that the data from over 50 million doses given to children in India reveals that side effects are minimal. The trials […]

Bharat Biotech’s Covaxin Gets Nod For Restricted Emergency Use For Children Aged 6-12

  NEW DELHI: The Drugs Controller General of India (DCGI) on Tuesday granted a restricted emergency use authorisation to Bharat Biotech’s Covaxin for children aged 6-12 years. Covaxin is one of the first COVID-19 vaccines in the world to generate data in the 2-18 year age group. The authorisation is given to Bharat Biotech after […]

Covaxin To Be Commercially Available In North America

  NEW DELHI: In a major development that will boost the world’s fight against the COVID-19 virus, Hyderabad-based Bharat Biotech on Thursday announced that its popular COVID vaccine Covaxin will now be commercially available in Mexico. The global leader in vaccine innovation, Bharat Biotech today announced that they have revised the agreement with US biotech […]

‘COVAXIN Shows Better Antibody Response In Children Aged Between 2-18 Years Than Adults’

NEW DELHI: Bharat Biotech International Limited confirms that COVAXIN successfully conducted the stage II/III study on children. The trials have proven to be safe, well tolerated and immunogenic among children. COVAXIN trails show even better response in children aged between 2-18 years than adults. Bharat Biotech conducted the phase II/III multicenter studies to evaluate the […]